diabetic retinopathy

CAY10746 is a selective Rho kinase (ROCK) inhibitor, targeting ROCK I and ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be employed in the study of diabetic retinopathy.

1, 5-Isoquinolinediol is an inhibitor of poly(ADP-ribose) synthetase (PARP1; IC50: 0.39 μM). The poly(ADP-ribose) polymerases (PARPs) form a family of enzymes with roles in DNA repair and apoptosis. 1, 5-Isoquinolinediol has been used to study the role of

Ascorbic acid, rutoside drug combination is used for treating diabetic retinopathy.

Diprotin A (Ile-Pro-Ile) is a dipeptidyl peptidase IV (DPP-IV) inhibitor.

VU0285655-1(BML-280) is a potent and selective phospholipase D2 (PLD2) inhibitor that inhibits the proliferation of PLD2-deficient cells.VU0285655-1 has an inhibitory effect on high glucose-induced caspase-3 cleavage and reduction of cell viability.VU0285655-1 is used in the study of diabetic retinopathy.

JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.

12-HETE ((±)12-HETE) is a modulator of PGE2, with both anti-thrombotic and pro-thrombotic effects, inducing PGE2 release and COX-2 expression via phospholipase A2 (sPLA2-IIA) inducers. It is also a neuroregulator activating retinal cell endothelial dysfunction in diabetic retinopathy.

Specnuezhenide (Nuezhenide) is isolated from the fruit of Ligustrum lucidum. It inhibits NF-κB and wnt β-catenin signaling, thereby suppressing IL-1β-induced chondrocyte inflammation. It exerts anti-inflammatory effects in a rat model of osteoarthritis (OA).

1. Obtusifolin has antioxidant properties and improves chemically induced diabetes and its complications by modulation of oxidative stress. 2. Obtusifolin suppresses phthalate esters-mediated bone resorption, thus may be a novel anti-breast-cancer bone me

Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabetic retinopathy [1].

Plasma kallikrein-IN-2, a potent inhibitor of plasma kallikrein (PKal) with an inhibitory concentration (IC) 50 value of 0.1 nM, is utilized in research targeting hereditary angioedema, diabetic macular edema, and diabetic retinopathy.

UBX1325, a Bcl-xL inhibitor, enhances apoptosis in senescent cells, serving as an effective anti-aging agent. It holds potential for age-related eye disease research, including diabetic macular oedema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR) [1].

CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic retinopathy, and inflammation [1].

CU06-1004 (Sac-1004) is an orally active compound that mitigates endothelial dysfunction by inhibiting hyperpermeability and inflammation. It reduces vascular leakage and inflammation in multiple animal models, including diabetic retinopathy, stroke, cancer, and inflammatory bowel disease. CU06-1004 also improves conditions in a CDAA-induced mouse model of NASH and enhances cardiac function [1] [2] [3].

Dammarenediol II may have the ability to prevent diabetic microvascular complications, including diabetic retinopathy, it can inhibit vascular endothelial growth factor (VEGF)-induced intracellular reactive oxygen species generation and stress fiber forma

Tridocosahexaenoylglycerol (TG-DHA), an orally active dietary supplement, enhances outcomes in autoimmune encephalomyelitis among mice, exhibits beneficial impacts on neurodegenerative conditions, and fosters macular function improvement in diabetic retinopathy. It is applicable for investigating neurological, inflammatory immune, and metabolic diseases [1] [2] [3].